Clinical Overview of Cytopenic Myelofibrosis and Pacritinib
This webinar is sponsored by:
Date: Thursday, November 10, 2022
Time: 12:00pm EST
Patrick Tamburro, PharmD – Medical Science Liaison
Description: This webinar will provide a brief overview of Myelofibrosis pathophysiology and symptomology with a focus on cytopenias and their association with poor prognosis,
Pacritinib’s mechanism of action, efficacy as well as safety in clinical trials across all platelet counts, and compassionate use program outcomes. Indication and latest National Comprehensive Cancer Network (NCCN) guidelines will also be covered with time for questions at the end.
- Recognize unmet needs for cytopenic myelofibrosis patients and poor prognosis associated with cytopenias
- Efficacy and Safety of pacritinib in clinical trials in patients with platelets counts below as well as above 50 × 109/L.
- Pacritinib’s indication
- Latest NCCN Guideline recommendations
Virtual Platform: GoToWebinar
Target Audience: Hematology/Oncology healthcare providers (MD,DO, PA, NP, RN)
CME/CE: 0 hrs
IMPORTANT: There is a 2 step registration process -
After registering on this site, you will receive a confirmation email with instructions to register with GoToWebinar to receive your logon instructions and calendar reminder.